Vyleesi Sexual Function Impact: What Bremelanotide Actually Does

What Bremelanotide Is and How It Works

Bremelanotide is a synthetic heptapeptide melanocortin receptor agonist that acts centrally to modulate pathways involved in sexual desire. The FDA granted approval on June 21, 2019, making it the second drug approved specifically for HSDD in premenopausal women, after flibanserin (Addyi) in 2015. Unlike flibanserin, which is taken daily, bremelanotide is dosed on demand.

Receptor Pharmacology

Bremelanotide binds with high affinity to MC3R and MC4R receptors in the central nervous system. MC4R activation in the hypothalamus has been linked to pro-erectile and pro-desire signaling in animal models, and early human trials confirmed dose-dependent increases in subjective arousal. The FDA prescribing label notes that the precise mechanism by which bremelanotide improves sexual desire in women with HSDD is not fully understood, though the melanocortin axis is considered central to the effect. Prescribing information is available at the FDA's accessdata portal.

Pharmacokinetics

After a 1.75 mg subcutaneous injection, peak plasma concentration is reached in approximately 1 hour. The half-life is roughly 2.7 hours. Bremelanotide undergoes hydrolysis and is not a CYP enzyme substrate, which reduces drug-interaction risk compared to flibanserin's CYP3A4 dependence. Patients should inject 45 minutes before sexual activity; onset of effect aligns with peak CNS exposure. The pharmacokinetic profile is detailed in the FDA's clinical pharmacology review.

The RECONNECT Trials: Core Efficacy Data

The RECONNECT program comprised two identically designed, randomized, double-blind, placebo-controlled phase 3 trials that together enrolled 1,247 premenopausal women diagnosed with HSDD. Results were published in Obstetrics and Gynecology in 2019. The primary publication is indexed at PubMed PMID 31060191.

Primary Endpoints

The trials used two co-primary endpoints measured over 24 weeks:

1. Change from baseline in the Female Sexual Function Index desire domain (FSFI-desire subscale), scored 0 to 6.
2. Change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13, which specifically measures distress related to low sexual desire.

Key Results

In the pooled RECONNECT analysis, bremelanotide produced a statistically significant improvement on both co-primary endpoints versus placebo. Approximately 24.5% of bremelanotide-treated women were classified as "responders," meaning they achieved a clinically meaningful improvement in desire, compared to 17.0% on placebo (P<0.05). The full efficacy tables are in the RECONNECT publication at PMID 31060191.

On the FSDS-DAO item 13, bremelanotide reduced distress scores by a mean of 0.5 points more than placebo over 24 weeks. While the absolute difference may appear modest, HSDD distress scores have high inter-patient variability, and regulators accepted this magnitude as clinically meaningful given the lack of alternatives and the patient burden of the condition.

The number needed to treat to produce one additional responder is approximately 13, a figure worth sharing with patients during counseling so expectations remain grounded. For context on responder thresholds in female sexual dysfunction trials, see the FDA guidance archived at fda.gov.

What the Trial Did Not Show

RECONNECT did not show a statistically significant improvement in arousal, lubrication, orgasm, satisfaction, or pain domain scores on the full FSFI instrument. The drug's labeled indication is specifically HSDD, and prescribing it for other sexual dysfunction subtypes goes beyond the evidence. FSFI domain structure and validation are described in detail at PMID 11535247.

How Bremelanotide Compares to Flibanserin

Flibanserin (Addyi), approved in 2015 for premenopausal HSDD, works via a different mechanism: 5-HT1A agonism and 5-HT2A antagonism with secondary dopamine and norepinephrine effects. The flibanserin approval history is documented at the FDA accessdata portal.

Mechanism Comparison

Flibanserin rebalances serotonin-dopamine signaling chronically. Bremelanotide stimulates MC3R/MC4R acutely. The two mechanisms are not redundant. A patient who does not respond to flibanserin may still respond to bremelanotide, and vice versa. No head-to-head trial has compared the two drugs directly, so clinical choice depends on patient lifestyle, tolerability, and preference. A practical comparison of both agents appears in a 2020 review at PMID 32072067.

Administration and Lifestyle Fit

Flibanserin requires daily dosing and carries a boxed warning for hypotension and syncope with alcohol. Bremelanotide is on-demand, carries no alcohol restriction, but does carry a transient blood pressure warning. For patients who drink alcohol occasionally, bremelanotide may be the more practical choice. The Addyi prescribing label with alcohol boxed warning is at accessdata.fda.gov.

Safety Profile and Adverse Effects

Nausea and Flushing

Nausea is the most common adverse effect, reported in approximately 40.4% of bremelanotide-treated women in RECONNECT versus 1.4% on placebo. Flushing occurred in 20.4% versus 0.9%. Both effects are transient, typically peaking within 1 hour of injection and resolving within 12 hours. Pre-treating with oral ondansetron 30 minutes before injection reduces nausea incidence; this approach is not in the label but is practiced clinically. Adverse event data from RECONNECT are in the primary publication at PMID 31060191.

Blood Pressure Elevation

Bremelanotide produces a transient, dose-dependent increase in blood pressure. In the phase 2 dose-escalation study, the 1.75 mg dose produced mean systolic BP increases of approximately 2 to 4 mmHg lasting about 12 hours. The FDA label contraindicates use in women with known cardiovascular disease and advises against use in uncontrolled hypertension. Baseline blood pressure should be recorded before the first prescription. The cardiovascular risk section of the bremelanotide label is at accessdata.fda.gov.

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breast tissue has been reported with repeated bremelanotide use, likely due to MC1R stimulation in melanocytes. The FDA label recommends discontinuing the drug if hyperpigmentation develops. This side effect is more relevant for patients expecting long-term use. Hyperpigmentation risk is described in the bremelanotide label at accessdata.fda.gov.

Injection Site Reactions

Injection site bruising, pain, and transient erythema were reported in about 22% of patients. These reactions are generally mild and resolve within hours. Teaching patients proper subcutaneous injection technique at the abdomen or thigh reduces local reactions. Injection site data are summarized in the FDA's medical review for bremelanotide, accessible via the NDA 210557 documents at accessdata.fda.gov.

Patient Selection: Who Is Most Likely to Benefit

Not every patient with low sexual desire has HSDD. The diagnosis requires both low desire and personal distress caused by that low desire. Patients with situational low desire (attributable to relationship conflict, partner dysfunction, or contextual stressors) are less likely to benefit from bremelanotide than those with generalized, acquired HSDD. The following framework helps identify candidates most likely to respond.

Diagnostic Criteria First

The DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD), which overlaps substantially with HSDD as defined in the RECONNECT trials, require at least 3 of 6 symptom criteria present for a minimum of 6 months, causing clinically significant distress. Prescribers should document distress explicitly, not just absent desire. DSM-5 FSIAD criteria are discussed in the context of clinical trials at PMID 26646568.

Ruling Out Reversible Causes

Before prescribing bremelanotide, clinicians should evaluate and address:

• Hormonal status. Low estrogen from perimenopause, hypothyroidism, hyperprolactinemia, and low androgen states all impair desire. A basic panel including TSH, prolactin, estradiol, and free testosterone is reasonable. Endocrine causes of low libido are reviewed at PMID 20378106.
• Medications. SSRIs and SNRIs reduce desire in a large proportion of users; dose reduction or switching to bupropion or mirtazapine may restore function without adding a second drug. SSRI-related sexual dysfunction is reviewed at PMID 30428164.
• Genitourinary syndrome of menopause (GSM). Pain with intercourse suppresses desire secondarily. Treating GSM with local estrogen or ospemifene may resolve the presenting complaint. NAMS position statement on GSM management is at PMID 23985636.
• Mental health. Depression, anxiety, and trauma histories all affect desire independently of biology. Concurrent psychotherapy or psychiatric management should accompany pharmacotherapy when relevant. The relationship between depression and female sexual dysfunction is described at PMID 15736318.

Ideal Candidate Profile

The patient most likely to benefit from bremelanotide is a premenopausal woman with acquired generalized HSDD, documented personal distress, no reversible hormonal or medication-related cause, and no contraindicated cardiovascular history. She prefers on-demand dosing over a daily pill and does not have a prior diagnosis of uncontrolled hypertension. She should understand before the first injection that the average benefit is modest and that nausea is common.

Practical Prescribing: Dosing and Administration

Bremelanotide comes as a single-use, prefilled autoinjector delivering 1.75 mg in 0.4 mL. The recommended injection site is the abdomen or thigh (not intramuscular). No dose adjustment is needed for mild-to-moderate hepatic or renal impairment, but the drug is not studied in severe hepatic impairment and should be avoided there. Full prescribing instructions are at the FDA label, accessdata.fda.gov.

Timing and Frequency

Patients should inject 45 minutes before anticipated sexual activity. The drug should not be used more than once in any 24-hour period. The label does not specify a maximum number of doses per month, but nausea frequency and potential hyperpigmentation risk suggest that daily or near-daily use is inadvisable. Real-world use patterns from the open-label extension of RECONNECT showed a median of approximately 2 injections per month among continuing users, consistent with planned rather than spontaneous sexual activity. Open-label extension safety data were submitted as part of NDA 210557 at accessdata.fda.gov.

Monitoring After Initiation

At the first follow-up visit (typically 4 to 8 weeks after initiating bremelanotide), the clinician should:

1. Reassess desire and distress using a validated instrument, ideally the FSFI and FSDS-DAO item 13 used in RECONNECT.
2. Ask specifically about nausea severity and whether it prevented sexual activity.
3. Inspect any areas of skin the patient identifies as discolored.
4. Check blood pressure if the patient reports headache or flushing that seems disproportionate.

If no meaningful improvement in desire or distress occurs after 8 weeks of use at typical frequency, discontinuation should be considered. Continued prescribing without re-evaluation perpetuates cost and side-effect exposure without documented benefit. Patient-reported outcome instruments in HSDD clinical trials are reviewed at PMID 21029394.

Role of Psychotherapy and Combination Approaches

Bremelanotide addresses the biological component of HSDD but does not address relationship dynamics, body image, trauma history, or cognitive patterns that sustain low desire. Sex therapy modalities including sensate focus, cognitive behavioral sex therapy, and mindfulness-based interventions all have evidence in female sexual dysfunction. A 2016 Cochrane review evaluated psychological interventions for female sexual dysfunction at cochranelibrary.com.

The 2021 ISSWSH (International Society for the Study of Women's Sexual Health) process-of-care pathway for HSDD recommends combining pharmacotherapy with psychoeducation and, where available, sex therapy. Neither bremelanotide nor flibanserin has been studied in a randomized trial against the combination of drug plus therapy, so the incremental benefit of combining both is inferred rather than proven. The ISSWSH process-of-care pathway is published at PMID 33485308.

Regulatory and Guideline Context

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends against routine androgen therapy for HSDD but acknowledges bremelanotide and flibanserin as approved options. The Endocrine Society guideline is at PMID 31751458. The American College of Obstetricians and Gynecologists (ACOG) has issued a committee opinion noting that both drugs are modestly effective and that shared decision-making around side effects and expectations is essential. ACOG's position is summarized in their committee resources at acog.org.

The North American Menopause Society (NAMS) 2022 hormone therapy position statement does not cover bremelanotide specifically, as it focuses on menopause, but NAMS has addressed HSDD in premenopausal women in its clinical guidance. NAMS 2022 hormone therapy position statement is available at menopause.org.

The FDA's Risk Evaluation and Mitigation Strategy (REMS) program for flibanserin does not apply to bremelanotide; prescribers do not need REMS certification to prescribe Vyleesi, which reduces a practical barrier present with flibanserin. The REMS situation is confirmed at the FDA's REMS database at accessdata.fda.gov.

Unresolved Questions and Ongoing Research

Several clinically relevant questions about bremelanotide remain unanswered as of mid-2025.

Postmenopausal Use

RECONNECT enrolled only premenopausal women. The label restricts the indication accordingly. Postmenopausal women with HSDD have a different hormonal milieu, and the efficacy and safety of bremelanotide in that population have not been established in a phase 3 trial. Off-label use in postmenopausal women occurs but lacks regulatory support. A review of HSDD in postmenopausal women is at PMID 30496640.

Long-Term Hyperpigmentation Risk

The longest available safety data come from the RECONNECT open-label extension, which followed patients for approximately 52 weeks. Whether hyperpigmentation progresses with use beyond 1 year, and whether it reverses after discontinuation, remains incompletely characterized.

Biomarkers of Response

No validated biomarker predicts which patients will respond to bremelanotide. Given the approximately 13 NNT, the majority of treated patients do not achieve meaningful benefit. Research into genetic variants of melanocortin receptors may eventually guide patient selection, but this is pre-clinical as of 2025. MC4R polymorphisms and behavior are reviewed at PMID 21909094.